Skip to content

Dr. Gülsen Mutluoglu

Active
Private limited companyfounded 2023active for 3 yearsKaasstraat 38, 3404 Landen, BelgiumKBO/BCE: BE 0805.221.744
Summary

Dr. Gülsen Mutluoglu has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €97,346 and a net result of €44,298. Its solvency ranks better than 69% of 20,720 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 29-08-2023 Normal situation
Activity
Medical imaging and medical laboratories NACE 86910and 3 others
Establishment unit
2.351.861.010 3404 Landen, since 11-09-2023
Financial year end
30 September
Peppol
Reachable since 02-06-2025

Board and ownership

Board
Shareholders
  • MUTLUOGLU Gülsenact of 31-08-2023

Financial position

98 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts to 30-09-2025
Gross margin
€60,128
▼ 12.9%
Turnover
≈ €170,000
estimated
Profit
€44,298
▼ 14.9%
Equity
€97,346
▲ 83.5%
Total assets
€123,205
▲ 7.4%
Score breakdownraises riskFounded in 2023lowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 4.98, cash €51,376Equity €97,346 (79.0% of total assets)Show the evidence

Checked score

Score 2025
98 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 82% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Strong
Solvency 100+29
equity 79.0% of total assets
Liquidity 94+36
short-term debt 20.1% · cash 41.7%
Profitability 100=
return on assets 36.0%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,173 companies, NACE 86, micro)
Last 24 months 12-2024: 0.3% 01-2025: 0.3%● unchanged vs 12-2024 02-2025: 0.4%▲ +0.1 percentage points vs 01-2025 03-2025: 0.4%● unchanged vs 02-2025 04-2025: 0.4%● unchanged vs 03-2025highest value 05-2025: < 0.1%▼ -0.4 percentage points vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026lowest value 06-2026: < 0.1%● unchanged vs 05-2026lowest value 07-2026: < 0.1%● unchanged vs 06-2026lowest value 08-2026: < 0.1%● unchanged vs 07-2026lowest value 09-2026: < 0.1%● unchanged vs 08-2026lowest value 10-2026: < 0.1%● unchanged vs 09-2026 11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €9,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 4.98 (1.86 in 2024), above the usual 1.5. Short-term debt is 20.1% and cash 41.7% of total assets. 21% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 80% on liquidity, 80% on profitability and 87% on growth.

The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 4.98, cash €51,376
NBB · annual accounts
lowers risk · Equity €97,346 (79.0% of total assets)
NBB · annual accounts
raises risk · Founded in 2023
Companies of this age fail more often than older ones. How much that weighs depends on the rest of the company's profile.
KBO
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 27-04-2026, 3 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
3 days early
2024
16 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 2 accounts on average 10 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
30-09-2026 year end05-11-2026 today30-04-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2023.
KBO publications

Recent changes

  1. · Gazette deed IncorporationFounding capital of €1,000, 50 shares · Founder: MUTLUOGLU Gülsen · Appointment: MUTLUOGLU Gülsen (director)
All 4 events

Comparable companies

These companies have the same main activity as Dr. Gülsen Mutluoglu: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €82,300 and €154,000, founded between 2022 and 2024.

CompanyTotal assetsGross margin
Dr. Gülsen Mutluoglu Landen€123,205€60,128
LAHEMA Meise€134,646€65,155
GDT IMAGING Amel€121,211€50,445
DENTAAL LABO DEGRAEVE Roeselare€140,896€46,405
Meditech Imaging Society Charleroi€93,404€60,081
AMLB Zedelgem€82,285€57,395
BY A TECHNOLOGIST Evere€154,272€76,729
Full comparison

Key facts about Dr. Gülsen Mutluoglu

What is the company number of Dr. Gülsen Mutluoglu?
The company number of Dr. Gülsen Mutluoglu is 0805.221.744. The VAT number is the same number with BE in front: BE 0805.221.744.
Where is Dr. Gülsen Mutluoglu based?
The registered office is at Kaasstraat 38, 3404 Landen.Company details
What does Dr. Gülsen Mutluoglu do?
According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
What is the legal form of Dr. Gülsen Mutluoglu?
The legal form of Dr. Gülsen Mutluoglu is Private limited company (BV).
When was Dr. Gülsen Mutluoglu founded?
Dr. Gülsen Mutluoglu was founded on 29-08-2023.
Is Dr. Gülsen Mutluoglu still active?
Yes, Dr. Gülsen Mutluoglu is an active enterprise in the KBO register.
What is the turnover of Dr. Gülsen Mutluoglu?
The turnover in financial year 2025 is ≈ €170,000. This figure is estimated from the gross margin of €60,128 and 33 comparable companies (NACE 869). It probably lies between €110,000 and €240,000.Financials
Is Dr. Gülsen Mutluoglu profitable?
In financial year 2025, Dr. Gülsen Mutluoglu made a profit of €44,298.
Where can I find the annual accounts of Dr. Gülsen Mutluoglu?
Dr. Gülsen Mutluoglu filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Dr. Gülsen Mutluoglu due?
Dr. Gülsen Mutluoglu must file the annual accounts for financial year 2026 by 30-04-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.